Vivos Therapeutics to Participate at the Q1 Virtual Investor Summit
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Q1 Virtual Investor Summit on March 23, 2021, at 1:30 PM ET. Key executives, including CEO Kirk Huntsman and CFO Brad Amman, will discuss the company's focus on innovative treatments for sleep-disordered breathing, particularly obstructive sleep apnea (OSA). The Vivos System offers a non-invasive, personalized therapy for patients, which has successfully treated over 15,000 patients globally. Interested investors can register for the presentation and access a replay afterward on Vivos' website.
- None.
- None.
Vivos management to present at 1:30 pm Eastern Time on March 23, 2021
HIGHLANDS RANCH, Colo., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that Kirk Huntsman, Chief Executive Officer, Brad Amman, Chief Financial Officer, and Ed Loew, Investor Relations Officer, will be presenting at the Q1 Virtual Investor Summit at 1:30 pm ET on March 23, 2021.
Vivos Therapeutics, Inc. will be presenting at the conference on Tuesday, March 23, 2021 at 1:30 pm Eastern Time. Investors interested in joining the Vivos presentation can register at the link below:
https://zoom.us/webinar/register/WN_ECswsVyuQ3W5lHquLoT0iQ
A replay of the presentation will be available for view following the presentation on Vivos’ website at: https://vivoslife.com/investor-relations/
About Vivos Therapeutics, Inc.
Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos oral appliances have proven effective in over 15,000 patients treated worldwide by more than 1,100 trained dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using the Vivos System.
For more information, visit www.vivoslife.com.
About The Investor Summit
The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 100 companies and over 300 institutional and retail investors.
Cautionary Note Regarding Forward-Looking Statements
This press release, the presentation referred to herein, and the statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as “may”, “should”, “expects”, “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC's website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos' expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Investor Relations Contact:
Edward Loew
Investor Relations Officer
(602) 903-0095
ed@vivoslife.com
Media Relations Contact:
Caitlin Kasunich / Jenny Robles
KCSA Strategic Communications
(212) 896-1241 / (917) 420-1444
ckasunich@kcsa.com / jrobles@kcsa.com
Wire Service Contact
InvestorWire (IW)
Los Angeles, California
www.InvestorWire.com
212.418.1217 Office
Editor@InvestorWire.com
FAQ
When is the Vivos Therapeutics presentation at the Investor Summit?
Who will present at the Vivos Therapeutics event on March 23, 2021?
What is the focus of Vivos Therapeutics' presentation?
How can investors access the Vivos Therapeutics presentation?
Where can I find the replay of Vivos Therapeutics' presentation?
